Loading
A shortage of red blood cells or haemoglobin, causing tiredness and breathlessness. In cancer it comes from the disease itself (marrow infiltration, bleeding, inflammation), from chemotherapy suppressing the marrow, and from some targeted drugs.
Present in 30-90% of patients depending on cancer and treatment; a defining feature of myeloma, MDS and leukaemia, and the dose-limiting toxicity of PARP inhibitors (olaparib, talazoparib) and of some ADCs and radioligands. Managed by treating the cause, iron replacement, red cell transfusion (with restrictive thresholds) and, cautiously, erythropoiesis-stimulating agents, which raise thrombosis risk and were linked to worse outcomes when used to high targets. Transfusion independence is an endpoint in MDS trials (luspatercept, imetelstat). Fatigue from anaemia is one of the most common and under-treated symptoms in oncology.
In plain words · CD235a marks red blood cells. In an immune test its job is the opposite of the others: it is used to find red cells so they can be excluded, because there are far too many of them to leave in.
Showing the target this term concerns: CD235a.
Shares Luspatercept, Lower-risk myelodysplastic syndromes, Transfusion support and anaemia management, Myelodysplastic syndromes / neoplasms (MDS).
Shares Luspatercept, Lower-risk myelodysplastic syndromes, Transfusion support and anaemia management, Myelodysplastic syndromes / neoplasms (MDS).
Shares Erythropoietin receptor (EPOR), Lower-risk myelodysplastic syndromes, Transfusion support and anaemia management, Primary myelofibrosis.
Shares Imetelstat, Luspatercept, Lower-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS).
Shares Luspatercept, Transfusion support and anaemia management, Primary myelofibrosis.
Shares Luspatercept, Transfusion support and anaemia management, Myelodysplastic syndromes / neoplasms (MDS).
Shares Imetelstat, Luspatercept, Lower-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS).
Shares Erythropoietin receptor (EPOR), Lower-risk myelodysplastic syndromes, Transfusion support and anaemia management.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/